Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children from 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections

Trial Profile

Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children from 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Modified vaccinia Ankara (Primary)
  • Indications Monkeypox; Orthopoxvirus infections; Smallpox
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Bavarian Nordic

Most Recent Events

  • 26 Jun 2025 According to a Bavarian Nordic media release, topline results from this trial are anticipated in the Q3 2025.
  • 29 Oct 2024 Status changed from not yet recruiting to recruiting, according to a Bavarian Nordic media release.
  • 29 Oct 2024 According to a Bavarian Nordic media release, first children have now been vaccinated in the study, which is currently enrolling in the Democratic Republic of Congo (DRC) with plans also to include sites in Uganda.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top